Correct, Celts. I've done the math. Remember, tho

Correct, Celts. I've done the math. Remember, though, we get only 20% of what Bob posted today. I assume that we will eventually strike a deal for a larger cut, but for now, it's only 20%. Of course, as we add sales staff, I am confident they will ultimately focus on PIMD where we will have 90%, but probably other cogs and other expenses will be pulled out. But let's assume 6 reps at $500K per month bringing in $36M in revs, with 2 reps dedicated to WRx and the remaining 4 to PIMD. To make things simple and to account for all expenses and taxes (ignore the NOL for the moment), let's just cut 85%, which results in a conservative earnings estimate of $5.4M for a company that is burning through a little cash now. In my strong opinion, the impact of the market learning that this little gem is turning a profit and putting up triple-digit revenues and earnings growth will keep the PE way above 20. (I'm a longtime IBD investor and have seen PE ratios in the hundreds.). With that said, I'll increase my OS assumption to 135M shares and calculate an eps of $.04. At a 20 PE, that's $.80. But the PE will be much higher as this tremendous growth story emerges. Indeed, I would be surprised with anything below a 50 PE. So I'll assume 50 and state my opinion that this fully-ramped up JV business with 6 sales reps will deliver the SCRC shareholder at least $2 PPS by mid- to late-2015. To me, that's worth waiting for, especially when this does not include RapiMeds and whatever else Bob has cooking for us. Good luck!